Laronidase
| Evidence Level: L5 | Predicted Indications: 1 |
Table of Contents
- Laronidase
Laronidase: Sanfilippo syndrome
One-Sentence Summary
Laronidase is a recombinant enzyme (alpha-L-iduronidase) originally used as enzyme replacement therapy for mucopolysaccharidosis type I (Hurler, Hurler-Scheie and Scheie syndromes). Much of this predicted indication overlaps with the existing approved use rather than being a true new use.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Not recorded in the local data |
| Predicted New Indication | Sanfilippo syndrome |
| TxGNN Prediction Score | 0.9922 |
| Evidence Level | L5 |
| Canada Market Status | Marketed (marketed DINs: 1 of 1) |
| Number of DINs | 1 (marketed: 1) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Currently, detailed mechanism of action data is not available in the compiled data. Based on known information, laronidase is a recombinant form of alpha-L-iduronidase, the enzyme that breaks down the glycosaminoglycans dermatan sulfate and heparan sulfate. Its efficacy in MPS I is established, and it is mechanistically plausible that it could act on tissues affected by the same substrate accumulation.
Skeletal involvement (dysostosis multiplex) is a recognised manifestation of MPS I itself. This predicted “new” indication therefore largely overlaps with the existing label. The high TxGNN score most likely reflects that overlap rather than true repurposing.
In vitro data show that laronidase is taken up by cultured fibroblasts and osteoblasts, mainly through mannose 6-phosphate receptors, and is transported to lysosomes. This supports a plausible cellular mechanism in skeletal tissue. However, clinical benefit on bone disease is reportedly limited, because the enzyme penetrates poorly into avascular cartilage and bone.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
| PMID | Year | Type | Journal | Key Findings |
|---|---|---|---|---|
| 25345091 | 2014 | Review | Pediatric Endocrinology Reviews | Overview of MPS I: caused by alpha-L-iduronidase deficiency, with a spectrum from severe Hurler disease to attenuated Scheie disease; diagnosis by urinary GAG pattern and enzyme assay |
| 12196045 | 2002 | Review (drug monograph) | BioDrugs | Early development of laronidase as enzyme replacement therapy for MPS I, including orphan drug designation and fast-track status |
| 18758061 | 2008 | In vitro study | Biological & Pharmaceutical Bulletin | Laronidase was taken up dose-dependently by MPS I fibroblasts and osteoblasts via M6P receptors and transported to lysosomes |
| 23127271 | 2012 | Case report | Pediatric Neurology | 6.5-year follow-up of a boy with Scheie syndrome on enzyme replacement therapy; overall decline and disease progression were noted |
Canada Market Information
| DIN | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 02254506 | ALDURAZYME | Not specified | Not specified |
Safety Considerations
- Drug Interactions: Two minor interactions were identified: chloroquine and procaine.
Please refer to the package insert for other safety information, including warnings and contraindications.
Conclusion and Next Steps
Decision: Hold
Rationale: The predicted indication largely overlaps with the already approved MPS I use, so it is not a distinct repurposing opportunity. No clinical trials exist, and the literature is limited to reviews, an in vitro study and a single case report. The enzyme also penetrates bone and cartilage poorly.
To proceed, the following is needed:
- Health Canada package insert warnings and contraindications (a blocking gap for safety screening)
- Detailed mechanism of action data
- Clinical data specifically on skeletal outcomes with laronidase
- A clear definition of whether this indication differs from the approved MPS I label
Note on the Second Predicted Indication (Sanfilippo Syndrome)
Sanfilippo syndrome (MPS III) was also predicted, with a TxGNN score of 0.9922. It is not recommended for pursuit (Hold, evidence level L4). MPS III results from deficiencies in different enzymes, not alpha-L-iduronidase, and intravenous enzyme replacement does not cross the blood-brain barrier effectively, while MPS III is mainly a neurological disease. The retrieved literature, including a randomised placebo-controlled Phase 3 trial of laronidase, concerns MPS I only. Those results must not be credited to Sanfilippo syndrome.
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.